Login
Menu ☰ x
  • Home
  • Special Interest Group Sessions_SIGs
Print

Special Interest Group sessions (virtual)

Special Interest Group (SIG) sessions are informal, discussion-based meetings designed to bring together groups with a common interest to discuss research challenges, issues, and opportunities. They are not scientific sessions and should not focus on presenting new research. 

Registration
  • Members, Members-In-Training — $0
  • Nonmembers — $25

Register once and gain access to all available recordings. Recordings will be available until Dec. 31 (11:59pm EST).

Register now button

2025 SIG Sessions Schedule

(all times are EDT)

June 10 
9 - 10:30am
Noon - 1:30pm
6 - 7:30pm
9 - 10:30pm 
June 12
9 - 10:30am
Noon - 1:30pm
9 - 10:30pm
June 24
9 - 10:30am 
Noon - 1:30pm
9 - 10:30pm
June 26
9 - 10:30am 
Noon - 1:30pm

2025 SIG Session Details

(all times are EDT)

Endpoints and trial design in inherited retinal diseases

June 10 | 9 - 10:30am

Organizers

Rachel Huckfeldt, MD, PhD
Massachusetts Eye and Ear

Jacque Duncan, MD, FARVO
University of California, San Francisco

The FFB Clinical Consortium’s Regulatory Endpoints and Trial Design for IRDs [REDI] Working Group used data from a prospective natural history study of USH2A-associated retinal degeneration (RUSH2A) to evaluate candidate endpoints for clinical trials for rod-cone degenerations and make recommendations in collaboration with diverse subject matter experts. We will present regulatory feedback received and how we are using it to further explore and optimize endpoints, including the case for full-field stimulus threshold as an approvable endpoint and ideas for establishing its clinical relevance There will be an open discussion about endpoint challenges in IRDs and potential pathways to establishing clinical relevance.

We will then review other trial design challenges. Even with the most sensitive endpoints, demonstrating treatment benefits, meeting all current standards (number of trials, number of treatment groups, type 1 error 0.05) within a feasible time frame and patient population is challenging, and demonstrating slowing of progression is even more difficult. An open discussion will follow, where attendees will be encouraged to discuss ideas for new trial design paradigms.

Presentations

Regulatory feedback on endpoint recommendations: REDI RUSH2A experience
Rachel Huckfeldt, MD, PhD
Massachusetts Eye and Ear

We will review key conclusions of the FFB Clinical Consortium’s Regulatory Endpoints and Trial Design for IRDs [REDI] Working Group with regard to RUSH2A and endpoints for rod-cone degenerations. We will then present the regulatory feedback received and how we are using it to further explore and optimize endpoints.

FST as a clinically relevant endpoint
David Birch, PhD
Retina Foundation of the Southwest, Dallas, Tex.

Full-field stimulus threshold (FST) was a sensitive measure in RUSH2A regardless of disease severity. A challenge, however, is that it is not viewed as clinically relevant. We will review the case for full-field stimulus threshold as an approvable endpoint and ideas for establishing its clinical relevance.

Please note that we plan to have an initial period for discussion focused on “Endpoint Challenges in IRDs” lasting approximately 30 minutes to be held after the 1st and 2nd talks and moderated by Dr. Jacque Duncan.

Beyond endpoints: Trial design challenges in IRDs
Todd Durham, PhD
Foundation Fighting Blindness, Columbia, Md.

An additional focus of the RUSH2A-based REDI analyses was modeling clinical trial design. We will review how endpoint choice and treatment effect impact trial duration as well as the number of participants needed. We will review the challenges that result particularly in the setting of rare diseases. A second period for discussion focused on “Trial Design Challenges in IRDs” lasting approximately 25 minutes will be held after this talk and moderated by Dr. Jacque Duncan.

Disclosures

Rachel Huckfeldt, MD, PhD
AGTC (F), Ascidian (F), Beacon Therapeutics (F), Biogen (F), BlueRock (C), Janssen (C, F),MeiraGTx (F), Saliogen (C), Sanofi (C), Sepul Bio (C, F), Sparing Vision (F), Spark Therapeutics(F), Splice Bio (C, F), Sunovion (C)

Jacque Duncan, MD
Acucela (F), Allergan/Abbvie (F), Ascidian (F), Biogen/NightstaRx (F), PYC Therapeutics(F),Sepulbio (F) ; participates on a DSMB or Advisory Board for NEI STEM trial (S), Spark Therapeutics Choroideremia trial (S), and AGTC X-linked retinoschisis trial (S)

David Birch, PhD
AGTC/Beacon (F), 4D MT (F), PYC Therapeutics (F), Ocugen (F), Scientific Advisory Board for Nacuity Pharma (S), Editas (C), 4D MT(C), PYC Therapeutics (C), ONL Therapeutics (C), Bluerock Therapeutics (C), Aldyra (C), SepulBio (C)

All other participants reported no relationships to disclose.

Harmonizing and designing novel endpoints in degenerative retinal diseases to foster innovation 

June 10 | 9 - 10:30am

Organizers

Nabin Paudel, PhD
Retina International

Avril Daly, MA
Retina International

Geographic atrophy (GA), an advanced from of dry Age-related Macular Degeneration is one of the leading causes of visual impairment and blindness in individuals over 50 years. Currently, only two GA therapies are available in the USA, while none have reached Europe—due to differing clinical trial endpoints criteria set by the FDA and EMA. Although both agencies accept anatomical endpoints, the EMA insists on measures with strong functional correlations. Many ongoing GA trials focus on anatomical outcomes—such as slowing lesion progression—as primary endpoints. However, European regulators question whether a reduction in lesion size translates into meaningful improvements in patients’ day-to-day lives. Therefore, it is crucial for stakeholders to - educate regulators on the nature of the disease, identify functional metrics that correlate with anatomical loss or to develop composite endpoints that better reflect tangible patient benefits.

This SIG meeting will bring together experts from industry, academia, regulatory bodies and patient organizations, to discuss current GA trial endpoints and explore strategies to address these challenges. Audience questions and insights are warmly welcomed. 

Panelists

Avril Daly, MA
Retina International

Sharon Bakalash, MD, PhD, CBA
Astellas Pharmaceuticals

Maximilian Pfau, MD, PhD
Clinician Scientist
Department of Ophthalmology, University of Basel, Basel, Switzerland
Department of Ophthalmology, University of Bonn, Bonn, Germany
Roche

Jane Moseley, MD
Senior Scientific Officer
Scientific Advice Office
European Medicines Agency

Moderator

Nabin Paudel, PhD
Retina International

Disclosures

Nabin Paudel, PhD
Retina International receives grant from multiple pharmaceutical companies to conduct specific studies and programs. No employee of RI is directly funded by the companies. In the past 24 months, we have received funding from: Roche –F, Apellis –F, Boeheringer Ingelheim – F, AstraZeneca –F, Johnson and Johnson Innovative Medicine- F, Amgen- F, Novartis - F

Avril Daly, MA
Retina International receives grant from multiple pharmaceutical companies to conduct specific studies and programs. No employee of RI is directly funded by the companies. In the past 24months, we have received funding from: Roche –F, Apellis –F, Boeheringer Ingelheim – F, AstraZeneca –F, Johnson and Johnson Innovative Medicine- F, Amgen- F, Novartis – F, Santen - F

Sharon Bakalash, MD, PhD, CBA
Astellas Pharmaceuticals – E, SB strategic development consultants LLC - C

Maximilian Pfau, MD, PhD
Roche (E)

Controversies in Dry Eye Disease (DED): Myth busting with DREAM data 

June 10 | Noon - 1:30pm

Organizers

Penny Asbell, MD, FACS, MBA, FARVO
University of Memphis, Biomedical engineering

Rony Sayegh, MD
Cole Eye Institute, Cleveland Clinic; Clinical Associate Professor, Lerner College of Medicine

Dry eye is a common problem that after years of research, clinical care and trials has led to many conclusions that often have not been replicated with robust clinical data. Using the standardized information gathered on over 500 subjects with moderate to severe DED, from the NEI funded DREAM randomized clinical trial, we will explore through panel discussion these questions: can noninvasive tests replace clinical assessments?, are inflammatory markers associated with worse DED?, do dry eye symptoms worsen with increasing age?, is atmospheric pollution associated with ocular inflammation?, can DED only be separated into evaporative and aqueous deficiency?, does DED progress with time?, does Omega 3 work for DED? Panelists will introduce the question and then the attendees and the panelists can all join in to the discussion. The results should help spur creative thinking on what is DED- how to diagnose, what are the pathological mechanisms and how best to approach clinical care. Results will help inform our future research and clinical care on ocular surface disease and dry eye.

Panelists

Vatinee Bunya, MD
Associate Professor, Cornea & External Disease
Scheie Eye Institute , University of Pennsylvania

Roni M. Shtein MD, MS
Associate Professor of Ophthalmology and Visual Sciences, University of Michigan

Loretta Szczotka-Flynn, OD, PhD
Searle-Huang Professor and Director, Vision Research Coordinating Center, Department of Ophthalmology and Visual Sciences, School of Medicine
Case Western Reserve University School of Medicine

Meng C. Lin, OD, PhD
Professor of Clinical Optometry & Vision Science
Herbert Wertheim School of Optometry and Vision Science
University of California

Reem Amine, MD
Cole Eye Institute, Cleveland Clinic

Disclosures

Penny Asbell, MD, FACS, MBA, FARVO
Premark, C Regeneron C , Santen C , Abbvie C, Amgen C, Harrow C, Glia C, Senju C , Trefoil C,Azura C, Iolyx C, LinkBiologic C

Vatinee Bunya, MD 
Kowa (C)--consultant, Sjogren's Foundation (S) --unpaid board member

Loretta Szczotka-Flynn, OD, PhD 
Epion (C)consultant and LenTechs (F) research F

Meng C. Lin, OD, PhD
(F): Alcon; Cooper Vision (C): Epitome Research and Innovations Inc.

All other participants reported no relationships to disclose.

Axon regeneration: What is required to reach the bedside?

June 10 | Noon - 1:30pm

Organizers

Molly Kennedy, B.S.
Bascom Palmer Eye Institute, Miami, FL 33136, USA

Michael Coronado, B.S.
Bascom Palmer Eye Institute, Miami, FL 33136, USA

Sanjoy K. Bhattacharya, Ph.D.
Bascom Palmer Eye Institute, Miami, FL 33136, USA

Axon regeneration is an exciting and promising area of research that holds the potential to transform the lives of patients suffering from diseases affecting their optic nerve, which can lead to irreversible vision loss. This Special Interest Group (SIG) session will explore the innovative approaches and methods in axon regeneration research, aiming to bridge the gap between laboratory discoveries and clinical applications. Functional recovery after axon damage in the central nervous system (CNS) remains limited, necessitating multidisciplinary research efforts to translate these findings into effective treatments. During this session, we will explore advances in axon regeneration, identify obstacles, and discuss potential solutions to overcome them. Attendees will be able to contribute their perspectives, fostering a collaborative environment to advance the progress of axon regeneration research. By bringing together diverse scientists and clinicians, we aim to pave the way for new therapies that will ultimately benefit patients and restore vision.

Presentations

Clinical considerations for developing optic nerve regeneration treatments: A neuro-ophthalmologist’s perspective.
Kimberly Gokoffski, MD, PhD
Keck School of Medicine, University of Southern California, Los Angeles

Regenerating the optic nerve to restore patient vision requires a multifaceted approach consisting of cells, molecules, and likely implanted devices. We will discuss clinical considerations regarding device design, including implantation strategies, and raise questions regarding standard outcome measures. Finally, questions regarding who is an ideal patient for treatment will be raised.

Optic nerve regeneration: A view from the RReSTORe Consortium
Thomas V Johnson, MD, PhD
Wilmer Eye Institute, Johns Hopkins University, Baltimore, Md.

I will discuss optic nerve regeneration in the context of end-stage optic neuropathy, which necessitates RGC repopulation and subsequent axonal extension through the anterior visual pathway. Leveraging insights gained through the RGC Repopulation, Stem Cell Transplantation, and Optic Nerve Regeneration (RReSTORe) Consortium (http://rrestore.info), I will discuss recent advances in transplantation of stem cell-derived RGCs and methods to encourage long-distance axonal extension and pathfinding from these cells in situ.

Improving axonal reconnection and functional recovery
Marc Hammarlund, PhD
Yale University School of Medicine, New Haven, Conn.

To restore circuits, axon regeneration requires axon growth and the formation of new synapses onto appropriate targets. Using C. elegans as a model, we conducted in vivo imaging of native synaptic proteins after synaptic reformation. We discovered that although grossly normal, regenerated synapses have fine-scale deficits in the localization of multiple key synaptic components and corresponding deficits in function. We tested numerous synaptic factors and identified a single manipulation that restores typical synaptic structure and function in regenerated axons. Together, these data identify how to improve functional outcomes after nerve injury.

Disclosures

Kimberly Gokoffski, MD, PhD
Dr. Gokoffski has served on Amgen's advisory board for the past 12 months. She states that this is not related to the work presented.

All other participants reported no relationships to disclose.

Standardizing structural and functional endpoints for inherited retinal disorders in clinical trials 

June 10 | 6 - 7:30pm

Organizer

Agha Yasin Alibhai, MD
Boston Image Reading Center

Recent advances in gene therapy and neurotrophic modulation have paved the way for novel and promising treatments for inherited retinal disorders (IRDs). However, establishing meaningful, repeatable, and time-sensitive structural and functional biomarkers remains a major challenge for IRD clinical trials.

Although several studies have documented changes in the photoreceptor, ellipsoid zone, and retinal pigment epithelium in IRDs, a standardized method to quantify these outer retinal changes has not been established. Meanwhile, fundus-driven microperimetry shows promise for quantifying and monitoring central visual function in IRDs, yet the definition of clinical improvement remains under discussion.

During this SIG, moderators will discuss and aim to help foster a conversation that will help standardize repeatable functional and clinical endpoints for IRD trials. We encourage you to bring your experiences, questions, and ideas to the discussion and help shape the future of IRD clinical trial design.

Panelists

Nadia K Waheed, MD, MPH
Department of Ophthalmology, Tufts University School of Medicine

Peter Zhao, MD
Department of Ophthalmology, Tufts University School of Medicine

Aniz Girach, MD
SpliceBio

Luisa Mendonca, MD, PhD
Boston Image Reading Center

Paul Yang, MD, Ph.D
Casey Eye Institute, Oregon Health & Science University School of Medicine

Disclosures

Agha Yasin Alibhai, MD
E - Boston Image Reading Center

Nadia K Waheed, MD, MPH
C - Nidek, Topcon, Olix Pharmaceuticals, Iolyx Pharmaceuticals, Aavantgarde Bio, SamsungBioepis, Alkeus Pharmaceuticals, E - Ocular Therapeutix, F - Zeiss, Topcon, Nidek, I - Ocudyne, Valitor, Beacon Therapeutics, Iolyx Pharmaceuticals

Aniz Girach, MD
E - SpliceBio

Luisa Mendonca, MD, PhD
E - Boston Image Reading Center

Setting up a lab as a new PI: Challenges and perspectives

June 10 | 9 - 10:30pm

Organizer

Raji Shyam, Assistant Professor
Indiana University Bloomington

This session will focus on identifying the common challenges facing new PIs in vision sciences. In this panel discussion, meet four new PIs who can provide insights into setting up your new lab. We will discuss strategies and challenges in hiring personnel, prioritizing projects, mentoring students, and grant writing during the initial years of setting up a new lab.

Panelists

Anna Matynia, Ph.D.
Associate Professor
University of Houston

Elizabeth Zuniga-Sanchez, Ph.D.
Assistant Professor
Baylor College of Medicine

Supraja Varadarajan, Ph.D.
Assistant Professor
UT Southwestern

Raji Shyam
Assistant Professor
Indiana University Bloomington

Disclosures

All participants reported no relationships to disclose.

Full-field Stimulus Threshold (FST) testing as a potential endpoint for regulatory consideration in clinical trials for inherited retinal diseases

June 12 | 9 - 10:30am

Organizer

Claire M. Gelfman, PhD
CMG Consulting

As inherited retinal disease (IRD) trials seek objective, reproducible functional measures to support clinical efficacy, Full-field Stimulus Threshold (FST) testing has emerged as a promising biomarker for disease progression and treatment response. The approval of Luxturna established a regulatory precedent for FST, demonstrating its potential as a tractable and modifiable endpoint that correlates with success in the multi-luminescence mobility test (MLMT). This session will bring together expert panelists, each involved in recent clinical trials where FST was a key secondary endpoint, tracking with disease progression and predicting success in the MLMT. Discussions will explore how FST has been leveraged in clinical trials for IRDs and natural history studies. Attendees will gain a deeper understanding of FST’s role in regulatory discussions and its potential as a primary clinical endpoint in future trials to assess efficacy of potential retinal disease therapies. This session will foster an interactive dialogue on data standardization, validation, and strategies for broader regulatory acceptance, inviting perspectives from researchers, clinicians, and industry stakeholders.

Panelists

Tomas S. Aleman, MD
Irene Heinz-Given and John LaPorte Research Professor
Attending Physician, Department of Ophthalmology, Hospital of the University of Pennsylvania
Director of the Retinal Structure and Function Laboratory, Perelman Center for Advanced Medicine, Perelman School of Medicine, University of Pennsylvania
Co-Director Center for Hereditary Retinal Degenerations, Scheie Eye Institute

Daniel C CHUNG, DO, MA
Chief Medical Officer
Sparing Vision

Artur V. Cideciyan, PhD
Research Professor of Ophthalmology
Scheie Eye Institute
Co-Director, Center for Hereditary Retinal Degenerations
University of Pennsylvania

Kenji Fujita, MD
Chief Medical Officer
Atsena Therapeutics

Rachel Huckfeldt, MD, PhD
Massachusetts Eye and Ear
Harvard Medical School
Boston, MA

Disclosures

Claire M. Gelfman, PhD
Visgenx (C), UC Berkeley Forum for Collaborative Research (C), Bluegen Therapeutics Foundation (C), FELIQS Corporation (C); Samsung (C); Abeona (C)

Tomas S. Aleman, MD
Virtual reality mobility test (PCT/US2019/029173 (P)
Editas Medicine, Inc. (C, F); Atsena Therapeutics, Inc. (C, F) ; Opus Genetics, Inc. (C, F)

Artur V. Cideciyan, PhD
Atsena Therapeutics (F), Opus Genetics (F,C), Thea (C), Alkeus (C), Ray Therapeutics (C), VCCell Therapy (C)

Rachel Huckfeldt, MD, PhD
AGTC/Beacon (F), Ascidian (F), Biogen (F), BlueRock (C), Janssen (C, F), MeiraGTx (F), Octant(C), Saliogen (C), Sanofi (C), Sepul Bio (C, F), Sparing Vision (F), Spark Therapeutics (F),Splice Bio (C, F), Sunovion (C)

Daniel C CHUNG, DO, MA
SparingVision (E)

Charles Bonnet Syndrome: New hallucinations

June 12 | 9 - 10:30am

Organizers

Dr. Jasleen K Jolly DPhil MSc FCOptom
Jolly Vision Science

Ceecee Britten-Jones PhD
Department of Optometry and Vision Science, University of Melbourne, VIC, Australia

Charles Bonnet Syndrome (CBS) is more common than previously thought and can occur after any type of vision loss. Much recent work has advanced knowledge about CBS and busted myths that were previously learned from small scale case studies. This SIG will discuss key areas of new knowledge and areas for future development in CBS work and how it relates to clinical practice. There will be 3 short talks followed by a question and answer session.

Presentations

Neuroscience of CBS
Jasleen K. Jolly, DPhil, MSc, FCOptom
Jolly Vision Science
Cambridge, UK

This talk will introduce the neuroscience of CBS and the evidence relating the underlying pathophysiology of the hallucinations.

CBS in children
Lee Jones, PhD
Institute of Ophthalmology
University College London, United Kingdom

This talk will review the experience of CBS in paediatric populations and new resources that have been designed specifically to address this patient population.

The Future of CBS care
Tamsin Callaghan, PhD, MCOptom, SFHEA
NIHR Royal Free Clinical Research Facility
Royal Free London NHS Foundation Trust, United Kingdom

This talk will review the effect of CBS symptoms on the quality of life in people with CBS and the role of podcasts in improving the management of hallucinations. This talk will review efforts in standardising care of patients with CBS and what directions future research needs to move in. This will lead into the discussion with the audience Beyond Endpoints: Trial Design Challenges in IRDs.

Disclosures

Jasleen K. Jolly, DPhil, MSc, FCOptom
S Choroideremia Research Foundation; C Sepul Bio Pharmaceuticals; C GenSight Therapeutics; C OKKO.

All other participants reported no relationships to disclose.

Vitreoschisis, vitreous cortex remnants, and hyalocytes: Novel insights into their role in PVR management

June 12 | Noon - 1:30pm

Organizers

Koen van Overdam, MD, PhD
Erasmus MC Rotterdam, The Netherlands

Peter van Etten
The Netherlands

Marc Veckeneer, MD, PhD
ZNA Middelheim Hospital in Antwerp, Belgium

This speaker session explores new insights into vitreoschisis, vitreous cortex remnants (VCR), and hyalocytes in the context of proliferative vitreoretinopathy (PVR) management. This session features leading experts who will discuss the latest research, pathophysiological mechanisms, surgical strategies, and clinical implications of VCR in PVR surgery.

Presentations

Vitreoschisis and VCR: Mechanisms, pathophysiology, and novel insights.
Jerry Sebag
VMR Institute for Vitreous Macula Retina
Huntington Beach, USA

This presentation explores the biochemistry and structure of the vitreous body, including collagen, hyaluronan, and their interactions. It discusses fibrous liquefaction, posterior vitreous detachment (PVD), and mechanisms of anomalous PVD. Special attention is given to posterior and peripheral vitreoschisis and their clinical significance in vitreo-maculopathy, retinal detachment, and proliferative vitreoretinopathy (PVR).

Hyalocytes and Their Role in VCR: A driver of PVR.
Stefaniya Boneva
Eye Center at the Medical Center, Faculty of Medicine
University of Freiburg in Baden-Württemberg, Germany

Immune cells have been implicated in the pathophysiology of proliferative vitreoretinopathy (PVR). Transcriptomic analyses and in vitro data hint at a possible transdifferentiation of vitreous macrophages, so-called hyalocytes, into myofibroblasts, contributing to scar formation during the course of PVR. We present hyalocytes as a potential target for future approaches in PVR treatment.

Potential Benefits of VCR Removal: Reducing PVR and improving surgical outcomes
Koen van Overdam, The Netherlands
Erasmus MC Rotterdam, The Netherlands

This presentation explores the clinical implications of hyalocyte-containing, vitreoschisis-induced vitreous cortex remnants (VCR) in retinal detachment vitrectomy. It presents evidence that intraoperative identification and removal of VCR may reduce postoperative proliferative vitreoretinopathy (PVR) formation and recurrence, thereby improving anatomical and functional outcomes.

Discussion and Q&A
Moderator: Peter van Etten, The Netherlands

Weighing perspectives and exploring future directions. 

Disclosures

All participants reported no relationships to disclose.

NF1 optic nerve glioma: a novel model for vision restoration research

June 12 | 9 - 10:30pm

Organizers

Zhigang He
Boston Children's Hospital

Petr Baranov, PhD
Massachusetts Eye and Ear

Kalyan C. Vinnakota, PhD
Curing NF & Vision Restoration Initiative Gilbert Family Foundation

A major advancement in vision research has been the development of interventions that promote neuronal survival and axon regeneration, leading to the launch of the NEI Audacious Goals Initiative (AGI) for Regenerative Medicine in 2013. However, much of this research relies on rodent optic nerve crush models, which have limitations such as rapid retinal ganglion cell(RGC) degeneration and a significant distance between the injury site and target structures. More clinically relevant models are needed to advance neuroprotection, regeneration, and vision restoration.

NF1 optic pathway glioma (NF1 OPG) presents a promising alternative model for both mechanistic studies and therapeutic exploration. Neurofibromatosis type 1 (NF1) mutations significantly increase the risk of developing gliomas, particularly in children, affecting the optic nerves, chiasm, tracts, and radiations—often leading to vision loss. Mouse models replicate many of these clinical features, including optic neuropathy, RGC loss, and vision impairment, yet effective treatments remain unavailable.

This SiG aims to bring together experts to discuss NF1 OPG biology, from clinical presentation to mouse models and their applications in understanding neuroinflammation, RGC loss, and advancing vision restoration. By fostering collaboration, we hope to attract more investigators to this field and accelerate progress toward effective interventions.

Panelists

Robert A Avery, DO
Associate Professor of Ophthalmology
Children's Hospital of Philadelphia

Yuan Zhu, PhD
Professor
Children's Cancer Fund Distinguished Professorship in Pediatric Oncology Research
University of Texas Southwestern Medical Center

Caroline Tang, MD, PhD
Assistant Professor
Departments of Neurology and Ophthalmology

Silmara de Lima
Assistant Professor, Department of Ophthalmology
University of Pittsburgh

Jeffrey Goldberg
Chair and Professor of Department of Ophthalmology
Stanford University

Disclosures

Zhigang He
My lab has a pending SRA with Dompe and I am a advisor of Axonis and Myrobalan.

Jeffrey Goldberg
Annexon, BioCryst, Dompe, Emmecell, Novoron, ONL Therapeutics, Perceive Bio, Peripherex, Thea

All other participants reported no relationships to disclose.

Advances in MGD diagnostics, treatment and management: perspectives from clinical science, basic science and artificial intelligence

June 12 | 9 - 10:30pm

Organizers

Meng C. Lin, OD, PhD
Professor, University of California, Berkeley, Herbert Wertheim School of Optometry and Vision Science; Director, UC Berkeley Clinical Research Center

Penny A. Asbell, MD
Professor, Biomedical Engineering, University of Memphis, Memphis TN and Visiting Professional Fellow, UNSW Medicine at UNSW, Sydney, Australia

Meibomian gland dysfunction (MGD) is one of the most prevalent ocular conditions encountered by eye care providers. MGD is often characterized by meibomian gland obstruction, resulting in altered quality and quantity of glandular secretion that may lead to disruption of ocular surface homeostasis and ocular discomfort. The panel discussion aims to further our understanding about this chronic disorder based on recent study findings. There are 4 topic: (1) updates on clinical practice guideline of MGD; (2) MGD clinical definition and how disease frequency varies with different diagnostic criteria and demographic factors; (3) understanding the relationship between MG morphology and function using AI-assisted metrics; and (4) the relationship between meibum composition and meibum quality. The knowledge gained from this discussion will identify gap in knowledge, improve our understanding of MGD and more clearly point us in the direction of the underlying mechanisms leading to MGD and ultimately improved patientcare. Attendees are encouraged to participate in the discussion.

Panelists

Reiko ARITA, MD, PhD
Itoh Clinic, LIME working group
Japan

Nawajes Mandal, PhD
Professor of Ophthalmology, Anatomy & Neurobiology, and Pharmaceutical Sciences, UTHSC.
Assistant Director of Research, Ophthalmology, Hamilton Eye Institute, UTHSC.
The University of Tennessee Health Science Center

Meng C. Lin, OD, PhD
Professor, University of California, Berkeley
Herbert Wertheim School of Optometry and Vision Science
Director, UC Berkeley Clinical Research Center

Fiona Stapleton, PhD, FCOptom, FTSE, AO
Scientia Professor, School of Optometry and Vision Science
Faculty of Medicine and Health
UNSW Sydney

Penny A. Asbell, MD
Professor, Biomedical Engineering
University of Memphis, Memphis TN
Visiting Professional Fellow, UNSW Medicine
UNSW, Sydney, Australia

Disclosures

Reiko ARITA, MD, PhD
P, C): Santen Pharmaceutical, Viatris Pharmaceutical, Tarsus, Alcon, Inami, Technopia, Rohto, Novoxel Japan, Dr. Fischer Pharmaceuticals; (F): Santen Pharmaceutical, Senju Pharmaceutical, Novartis, Tarsus, Alcon, Inami, Technopia, Novoxel Japan, Dr. Fischer Pharmaceuticals

Meng C. Lin, OD, PhD
(F): Alcon; Cooper Vision, (C): Epitome Research and Innovations Inc.

Fiona Stapleton, PhD FCOptom FTSE AO
(F): Alcon, Azura, nthalmics, Roche, IOLYX; (C): Exonate, Novartis, Menicon, Alcon, Azura, Mentholatum, CSL, Seqiru, InMode

Penny A. Asbell, MD
Link Biologic (C), Premark(C), Regeneron (C), Santen (C), Abbvie (C), Amgen (C), Harrow (C),Glia (C), Senju (C),Trefoil C, Azura (C), Iolyx (C)

All other participants reported no relationships to disclose.

Assessing efficacy in early phase trials for IRDs by expecting the unexpected: A tribute to the late Samuel G. Jacobson, MD, PhD

June 24 | 9 - 10:30am

Organizer

Artur V. Cideciyan, PhD
University of Pennsylvania

Inherited retinal diseases (IRDs) in the pre-molecular era were classified by history, ophthalmoscopic appearance, visual field defects, and ERG. Initial steps into the molecular era appeared to suggest a direct link between the function of mutated genes and distinct clinical diagnoses. But evidence of complexity quickly emerged. Samuel G. Jacobson, MD, PhD, was at the cutting edge of the molecular transformation of IRDs that are now known to be caused by thousands of variants in more than 300 genes. Dr. Jacobson defined the approaches that link molecular and pre-clinical research with clinical measurements. All speakers had a close connection to Dr. Jacobson as colleagues and collaborators and they will describe aspects of deep phenotyping in IRDs that directly led to unexpected and enlightening discoveries while evaluating efficacy in early phase trials. Attendees will contribute to the discussion with their perspectives on past, ongoing and planned clinical trials for IRDs.

Presentations

Co-localized structure-function relationship to predict vision improvement potential in early phase gene-based trials for IRDs
Artur V. Cideciyan, PhD
Center for Hereditary Retinal Degenerations, Scheie Eye Institute
University of Pennsylvania

Inherited retinal diseases (IRDs) are a genetically heterogenous group of disorders that cause vision loss through degeneration or dysfunction of retinal photoreceptors, or both. Gene-based therapies aim to correct the underlying molecular defects to arrest further degeneration, or to ameliorate the dysfunction. Retinas with large functional defects despite retaining relatively preserved cellular architecture are predicted to demonstrate fast and large improvements upon efficacious therapy. This presentation will review previous modeling of quantitative structure function relationships using quantum catch-based photoreceptor physiology as well as pattern classification-based artificial intelligence. Predictions before clinical trials will be compared to measurements obtained after successful trials.

Combination of objective and subjective evidence to evaluate efficacy in early phase gene-based trials for IRDs
Tomas S. Aleman, MD
Center for Hereditary Retinal Degenerations, Scheie Eye Institute
University of Pennsylvania

Conventional measures of vision, such as high contrast visual acuity or light-adapted computerized perimetry are often not sufficiently able to describe the functional deficits experienced by patients with IRDs. The complexity and/or the severity of the vision loss in IRDs often exceeds the dynamic range of clinically available instruments, while conventional clinical vision tests do not relate well with the mechanisms of the visual dysfunction. This presentation will explore the different scenarios faced by the introduction of gene therapy as an option in pre-clinical translational work, in clinical trials and the IRD clinic. The presentation will cover the response to the challenges with the development of full-field electroretinography, perceptual and objective pupillometric measures of vision. The presentation will also cover the development of measures of functional vision or testing real-world visual performance of patients with IRD with the use of physical as well as virtual orientation and mobility tests.

High-resolution imaging to provide new insights into retinal degeneration
Jacque L. Duncan, MD, FARVO
Department of Ophthalmology
University of California San Francisco

Inherited retinal degeneration results from pathogenic variants in at least 300 genes, but many share similarities in their effect on vision. In rod-cone degenerations, night vision and midperipheral visual field is lost, with relative preservation of central vision mediated by macular and foveal cones. Cone degeneration follows rod loss, and loss of cone vision is particularly devastating to patients. High resolution images of cone structure and function from multimodal imaging, using optical coherence tomography and adaptive optics scanning light ophthalmoscopy, have provided insight into the distinct way cones are affected by different forms of inherited retinal degeneration. Functional measures are possible at cellular scale using subjective tests through adaptive optics microperimetry, and objective tests like optoretinography. Characterization of cone structure and function with high resolution can define disease progression and may be used to measure response to novel therapies in distinct forms of inherited retinal degeneration, including NR2E3 and USH2A-related retinal degenerations.

Disclosures

Artur V. Cideciyan, PhD.
Samuel G Jacobson, MD, PhD, Memorial Fund (F), Research to Prevent Blindness (F), Atsena Therapeutics (F,C), Opus Genetics (F,C),. Thea (C), Alkeus (C), Ray Therapeutics (C), VC Cell Therapy (C).

Tomas S. Aleman, MD
Research to Prevent Blindness (F), Atsena Therapeutics (F), Opus Genetics (F), Editas Medicine (F).

Jacque L. Duncan, MD
Acucela (F), Allergan/Abbvie (F), Biogen/NightstaRx (F), PYC Therapeutics (F); participates on a DSMB or Advisory Board for NEI STEM trial (S), Spark Therapeutics Choroideremia trial (S), and AGTC X-linked retinoschisis trial (S).

Mathematical and computational ophthalmology

June 24 | 9 - 10:30am

Organizers

Paul Allen Roberts, MMath, DPhil
Department of Optometry and Visual Sciences, City St George’s, University of London, London, United Kingdom

Peter Woodward-Court, BSc, MBBS, MRes
University College London, Moorfields Eye Hospital

This SIG will serve three purposes: 1) to bring together quantitative/biomedical scientists &clinicians using quantitative methods in ophthalmology; 2) to summarise the current state of affairs; 3) to clarify future directions & foster new collaborations.

Presentations

Challenges and opportunities in mathematical modelling in ophthalmology
Jennifer H. Tweedy, MA, MMath, PhD
University of Bath

In this talk I will discuss our experiences of mathematical modelling of physiological and pathophysiological processes in ophthalmology, as well as medical interventions. I will put forward some of the main advantages and potential benefits of using mathematical modelling, which include providing a deeper understanding of underlying mechanisms and frequently being a cheaper, and potentially quicker, alternative to experimental work. I will also discuss some of the challenges that are frequently encountered in this fascinating field.

The robustness of vision-language models to medical image artefacts
Yukun Zhou, BEng, MSc, PhD
University College London

Imaging artefacts are common in medical images and can hinder accurate disease diagnosis. Robustness to imaging artefacts is essential to support safe and trustworthy clinical decision-making. The recent literature has shown the promising potential of Vision-Language models(VLMs) in healthcare applications. However, their performance, particularly robustness to medical imaging artefacts, has not been thoroughly evaluated.

Synthetic imaging data in ophthalmic imaging
Peter Woodward-Court, BSc, MBBS, MRes
University College London
Moorfields Eye Hospital

This talk explores how synthetic OCT data—generated through advanced mathematical modeling and computational techniques—can simulate realistic retinal images for research and clinical applications. By creating high-fidelity synthetic datasets, we can overcome limitations associated with scarce or variable clinical data, enabling more robust training and validation of diagnostic algorithms. The approach not only accelerates the development of scalable, data-driven tools in ophthalmology but also deepens our understanding of retinal structure and disease progression.

Disclosures

All participants reported no relationships to disclose.

Modeling military visual injury

June 24 | Noon - 1:30pm

Organizers

Stephen C. Pflugfelder, MD, FARVO
Baylor College of Medicine

Richard Blanch
University Hospitals Birmingham NHS Foundation Trust

The purpose of the SIG is to examine the evolving landscape of eye and adnexal injuries in modern warfare and the military-relevant models used to study visual trauma. Panelists will explore the epidemiology and range of war-related ocular injuries, including damage to the eyelid, ocular surface/cornea, ciliary body, retina, and optic nerve. They will assess the strengths and limitations of current injury models, identifying gaps and areas for improvement. Discussions will focus on the development of more effective models and the key features needed in future research to better address the complex challenges faced by war-injured patients.

Panelists

Stephen C. Pflugfelder, M.D.
Baylor College of Medicine

Richard Blanch
University Hospitals Birmingham NHS Foundation Trust

Eva Chou, MD, FACS
Associate Professor, Department of Surgery, USUHS
Oculoplastic Surgeon, ATAMMC & WRNMMC

Brittany Powell, MD
Vitreoretinal Surgeon, Naval Medical Center San Diego Ophthalmology
Assistant Professor of Surgery, Uniformed Services University of the Health Sciences

Jonathan Myers, MD
Wills Eye Hospital
Thomas Jefferson University

Disclosures

Stephen C. Pflugfelder, MD
Alcon: C, F; Dompe: C, F; Kala: C; Kowa: C; Unfold: O

Jonathan Myers, MD
Grant Support: Abbvie: F; Avisi: C,F; Elios: F; Glaukos: C,F; Laboratories Thea: F; Olleyes: C

All other participants reported no relationships to disclose.

Unraveling the mechanisms of development of RPE changes and atrophy following subretinal gene therapy

June 24 | Noon - 1:30pm

Organizers

Luisa Mendonca, MD PhD
Boston Image Reading Center, Boston, MA, USA

Nadia K Waheed, MD MPH
New England Eye Center at Tufts, Boston, MA, USA

Gene therapy offers a unique approach to treating retinal diseases using a single-dose therapy. Different delivery routes can be used: intravitreal, subretinal, and suprachoroidal, each with particular implications. The subretinal administration of gene therapy involves the creation of aretinotomy with a localized injection of the therapeutic agent, leading to a contained retinal detachment, known as the subretinal bleb. RPE changes within or outside the subretinal blebsite have been reported following subretinal gene therapy in a few studies in the literature, but the knowledge on the mechanisms of development of this adverse event, patterns of progression and potential preventative actions is still limited. On this SIG, moderators will share key findings and open the floor for world-known experts in the field to dive into the possible mechanisms involved in the development of RPE changes following gene therapy(inflammation, transduction-related toxicity, other); the impact of the surgical procedure on the development of RPE changes; the dose-dependent nature of the lesions and patterns of progression seen to date. This SIG has been designed to be an interactive session, questions from the audience are encouraged.

Panelists

Peter A. Campochiaro, MD
Departments of Ophthalmology and Neuroscience, Johns Hopkins University School of Medicine,
Baltimore, Md.

Jeffrey S. Heier, MD
Ophthalmic Consultants of Boston, Mass.

Szilárd Kiss, MD, FASRS
Ophthalmology, Weill Cornell Medicine, NY

Robert MacLaren, MB ChB DPhil FRCOphth FRCS FACS FMedSci
Ophthalmology, University of Oxford, United Kingdom

Mark Pennesi MD, PhD
Casey Eye Institute, School of Medicine, Portland, Ore.

Disclosures

Nadia K Waheed, MD MPH
F: Zeiss, Topcon, Nidek; C: Nidek, Topcon, Olix Pharma, Iolyx Pharmaceuticals, Aavantgarde Bio, Samsung Bioepis,Alkeus Pharmaceuticals; I: Ocudyne, Valitor, Beacon Therapeutics, Iolyx Pharmaceuticals; E: Ocular Therapeutix

Peter A. Campochiaro, MD
F: RegenxBio, Genentech, Cove, Sanofi, Cellanese, Regeneron, ExgenesisBio, OcularTherapeutix; C: Boehringer Ingelheim Pharmaceuticals, Inc, Bausch and Lomb, Clearside, Cove,ExgenesisBio, Exonate, Ltd, Janssen Research & Development, Llc, Lilly USA Inc, Merck; and Co, Inc, Perfuse, Wave Life Sciences; I: Allegro, Cove

Szilárd Kiss, MD, FASRS
C: Beacon Therapeutics, Novartis, Optos, Genentech/Roche, Regeneron; O: Blue Gen Therapeutics Foundation; S: Adverum; P: Gene Therapy for AMD, Gene Therapy for Batten’s Disease, Cell Therapy for CMV Retinitis (assigned to Weill Cornell Medicine/Cornell University)

Robert MacLaren
P: Robert MacLaren is a named inventor on several retinal gene therapy patents owned by the University of Oxford and licensed for commercial use. C: Beacon Therapeutics, Scribe Therapeutics, SpliceBio, Biogen Inc, Zeiss and Novartis

Jeffrey Heier
C: 4DMT, Abbvie, Affamed, Alimera, Alkeus, Allegro, Annexon, Apellis, Asclepix, Astellas, Aviceda, Beacon Therapeutics, Boehringer Ingelheim, Breye Therapeutics, Cogent, Complement, Curacle, Daiichi Sankyo, Emmecell, Frontera, Galimedix, Harrow, Janssen R&D, Kaigene, Nanoscope, Notal Vision, Novartis, Ocuphire, OcuTerra, Opthea, Osanni Bio, Perceive Bio, Ray Therapeutics, Regeneron, Samsung Bioepis, Sanofi, Skyline Therapeutics, Stealth Biotherapeutics, Thea Laboratories, Unity Biotech, Vanotech, Visgenx, Vitranu. S: Akouos; F: 4DMT, AbbVie/Regenxbio, Annexon, Apellis, Ashvattha, Astellas, Bayer, Beacon Therapeutics, Cognition, Curacle, Iveric, Janssen R&D, Kodiak, Notal Vision, Novartis, Oculis, Opthea, Perceive Bio, Sanofi, Skyline Therapeutics, Stealth Biotherapeutics, Vanotech. I: Adverum, Aldeyra, Alzheon, Aviceda, Caeregen, jCyte, Manistee, Ocuphire, Ocular Therapeutix, Osanni Bio, Ray Therapeutics, RevOpsis, Vinci, Visgenx, Vitranu. E: Ocular Therapeutix.

All other participants reported no relationships to disclose.

Challenges and prospects of AI vision research collaborations across nations

June 24 | 9 - 10:30pm

Organizers

Haotian Lin, MD, PhD
Zhongshan Ophthalmic Center, Sun Yat-sen University

Neil Bressler, MD
Wilmer Eye Institute, John Hopkins University School of Medicine

In the new era where medicine and technology converge, artificial intelligence (AI) is reshaping the landscape of healthcare at an unprecedented pace. Ophthalmology, as a field that heavily relies on extensive imaging data analysis, has become a frontier for AI research and application. From deep learning-based automated screening of diabetic retinopathy to the diagnosis and prediction of blinding eye diseases such as cataracts and glaucoma, and even to navigation support for complex ocular surgeries, AI is driving a qualitative leap in the field with remarkable efficiency and precision. However, behind this progress lie substantial challenges and opportunities, particularly in the context of international collaboration and application across different regulatory guidelines and policies. Key issues such as data sharing across countries and regions, establishing standardized protocols, coordinating regulations, and addressing ethical concerns likely will be crucial in determining the future development of AI in ophthalmology.

This SiG virtual meeting, themed "Challenges and Prospects of AI Vision Research Collaborations Across Nations," aims to bring together voices from academia, clinical practice, and government agencies worldwide. Through in-depth interdisciplinary and cross-regional discussions, we seek to provide guidance regarding the future of this promising yet highly challenging field. The meeting aims to provide a high-quality dialogue platform to identify bottlenecks in AI ophthalmology research and regulatory implementation, explore pathways for international collaboration, and inspire the next wave of technological innovations and industrial advancements.

Panelists

Xiaohang Wu, MD, PhD
Zhongshan Ophthalmic Center, Sun Yat-sen University

Taraprasad Das, MD, FRCS, DSc
L V Prasad Eye Institute

T .Y. Alvin Liu, MD
Wilmer Eye Institute

Stuart Keel, PhD
World Health Organization

Carol Y. Cheung, PhD
The Chinese University of Hong Kong

Disclosures

Neil Bressler, MD
Editor in Chief, JAMA Ophthalmology; JAEB Center for Health Research Board of Directors;Research Grants to Johns Hopkins University School of Medicine from RegeneronPharmaceuticals, Inc.

All other participants reported no relationships to disclose.

Leveraging big data and AI for clinical trial design: Opportunities, challenges, and regulatory considerations

June 24 | 9 - 10:30pm

Organizers

Matthew Cheung
Ocular Therapeutix

Namrata Saroj, OD
Ocular Therapeutix

The increasing availability of real-world clinical data (RWD) and artificial intelligence (AI) is transforming clinical trial design, enabling more efficient patient recruitment, optimized study protocols, and data-driven decision-making. However, challenges remain in integrating diverse data sources, and navigating evolving regulatory frameworks.

This session will explore best practices for leveraging RWD in clinical trials, the role of AI in predictive modeling, and regulatory guidance on real-world evidence (RWE) for trial approval. Through expert insights and interactive dialogue, attendees will gain a deeper understanding of how big data is shaping the next generation of ophthalmic clinical research.

Presentations

Optimizing clinical trial design with real-world data
Adnan Tufail, MBBS, MD, FRCOphth
Moorfields Eye Hospital & Institute of Ophthalmology University College London

This presentation will explore how real-world clinical data (RWD) from electronic health records(EHRs), claims databases, and patient registries can inform and enhance clinical trial design. Topics will include strategies for using RWD to improve patient selection, refine eligibility criteria, and assess trial feasibility.

AI-driven approaches for patient selection and trial optimization
Daniel SW Ting, MD, PhD
Singapore National Eye Center

AI and machine learning are revolutionizing patient recruitment, stratification, and predictive analytics in clinical trials. This presentation will explore how AI can enhance biomarker-based patient selection, optimize trial design, and enable automated analysis of ophthalmic imaging data. Discussion will include challenges in AI model validation, data harmonization, and ensuring AI-driven insights are clinically meaningful. While regulatory agencies are increasingly evaluating AI applications in clinical research, this talk will focus primarily on the technical and practical aspects of AI implementation, with a brief overview of regulatory considerations.

Regulatory considerations for uUsing real-world data in clinical trials
Nadia Waheed, MD, MPH
Tufts Medical Center Ophthalmology and New England Eye Center – Boston

As regulatory agencies expand their guidance on real-world evidence (RWE) for clinical trials, understanding compliance requirements is critical. This presentation will provide an overview of FDA, EMA, and other global regulatory perspectives on incorporating RWD into clinical trial designs, external control arms, and post-marketing studies. Key topics will include best practices for data collection, validation, and submission to regulatory bodies to support trial approval and label expansion efforts.

Disclosures

Namrata Saroj, OD
Allegro, C, I; Amgen, C; Apellis, C; iRenix, C, I; Ocular Therapeutix, E; Pr3vent, I; RegenxBio,C; SamaCare, C, I.

Adnan Tufail, MBBS, MD, FRCOphth
AbbVie, C; Adverum, C; Annexon, C; Apellis Pharmaceuticals, C; Aviceda Therapeutics, C;Bayer, C; Boehringer Ingelheim, C; EyePoint Pharmaceuticals, C; Genentech-Roche, C; IvericBio, C; Janssen Pharmaceuticals, C; Nanoscope, C; Novartis, C; Ocular Therapeutix, C; Opthea,C; Oxurion, C; Regenxbio, C; Thea Pharma, C

Nadia Waheed, MD, MPH
AGTC, E; Complement Therapeutics, C; Gyroscope, I (Previous Equity Holder); Iolyx, C, E;Nidek, C, F; Novartis, C; Ocudyne, C, E; Ocular Therapeutix, E; Olix, C; Regeneron, F;Saliogen, C; Stealth, C; Topcon, C; Valitor, C; Zeiss, F

Challenges in conjunctival intraepithelial melanocytic lesions for oncologists and pathologists: How we resolve these issues by a multidisciplinary team approach

June 26 | 9 - 10:30am

Organizers

Martina C. Herwig-Carl, MD, FEBO
University Eye Hospital Bonn, Division of Ophthalmic Pathology

Anita CHAN Sook Yee, FRCpath, FAMS, FRCS(Ed), M Med(Ophth), MBBS
Singapore National Eye Center

Saumya Jakati, MBBS, MD
Associate Pathologist, Ophthalmic Pathology Laboratory, Kallam Anji Reddy Campus, LV PrasadEye Institute, Hyderabad, India

Conjunctival Intraepithelial Melanocytic Lesions (CMIL) present challenges both clinically and pathologically. Clinically, the management of these lesions requires balancing effective tumor control with minimizing side effects from treatment. In addition, the topical treatment options are reduced as interferon alpha-2b is no longer available. Pathologically, there are different classification systems available to grade these lesions. How can the pathologist make sure that the treating ophthalmologist understand the pathology report given the changing classification systems? These topics will be addressed with renowned experts in this field.

Presentations

Pathological classifications of conjunctival melanocytic intraepithelial lesions
Sarah E. Coupland, MBBS, PhD, FRCPath, FARVO, FSB
Lead, Liverpool and Moorfields Eye Path Services

George Holt
Chair of Pathology, Liverpool, United Kingdom

Conjunctival melanocytic intraepithelial lesions (C-MIL) can progress into conjunctival melanoma. Different classifications exist up to now. The historical perspective and pathological background of the C-MIL system will be illustrated and explained in this talk by Sarah Coupland who has been involved in the development of the most important classification systems.

How does the clinician handle conjunctival PAM, c-MIN, c-MIL?
Carol L Shields, MD
Ocular Oncology Service, Chief
Wills Eye Hospital

The treatment of conjunctival melanocytic intraepithelial lesions is challenging, in particular since Interferon alpha2b is no longer available. Current treatment regimens are presented and discussed from one of the most experienced ophthalmic oncologists in the field.

Practical implications for ophthalmologists and pathologists: How can we ensure that we speak the same language?
Tatyana Milman, MD
Professor, Ophthalmology and Pathology, Wills Eye Hospital

Case-based practical examples of the pathologist's reporting of CMIL with an emphasis on communication of findings that will guide the patient's care.

Disclosures

Anita CHAN Sook Yee, FRCpath, FAMS, FRCS(Ed), M Med(Ophth), MBBS
Honorarium 2024 Roche (R); Research funding 2016-2023 for VRL research Menarini Biomarkers Singapore (F)

All other participants reported no relationships to disclose.

Exploring the clinical applications of tear fluid biomarkers: from pediatric conditions to neurodegenerative diseases

June 26 | 9 - 10:30am

Organizers

Marlies Gijs
University Eye Clinic, Maastricht University, The Netherlands

Piera Versura
Universitaria di Bologna, Italy

Penny Asbell
University of Memphis, United States

Tear fluid is an emerging, non-invasive source of biomarkers with significant clinical potential across various patient groups. This session will explore its applications in diagnosing and monitoring diseases at different life stages. Dr. Sheila Angeles-Han will discuss tear fluid biomarkers in pediatric patients, including ROP and juvenile idiopathic arthritis (JIA). Prof. Stephanie Joachim will explore their use in adult surgical patients, from cataract to refractive procedures. Dr. Marlies Gijs will highlight applications in elderly populations, focusing on glaucoma and age-related neurodegenerative diseases.

Ophthalmologists Dr. Piera Versura and Dr. Penny Asbell will moderate the session and share their views on the clinical aspects. During this Special Interest Group session, attendees will have the opportunity to interact directly with experts, ask questions, and contribute to the conversation, fostering a dynamic exchange of ideas on the clinical potential of tear fluid biomarkers.

Presentations

Tear fluid biomarkers in pediatric patients, including ROP and juvenile idiopathicarthritis (JIA)
Sheila Angeles-Han
Division of Rheumatology, Cincinnati Children’s Hospital Medical Center
University of Cincinnati

The presentation will focus on the applications of tear fluid biomarkers in children, particularly their role in diagnosing and monitoring pediatric conditions like retinopathy of prematurity(ROP) and juvenile idiopathic arthritis (JIA). The discussion will highlight recent advancements in tear biomarker research, emphasizing its non-invasive nature and clinical significance inpediatric ophthalmology.

The use of tear fluid biomarkers in adult surgical patients, from cataract to refractive procedures
Stephanie Joachim
Experimental Eye Research Institute, University Eye Hospital
Ruhr-University Bochum, Germany

The presentation will focus on the use of tear fluid biomarkers in adult surgical patients, particularly their applications in procedures ranging from cataract surgery to refractive surgeries. It will explore how these biomarkers can help assess ocular surface health, predict surgical outcomes, and monitor post-operative recovery.

Applications of tear fluid biomarkers in elderly populations, focusing on glaucoma and age-related neurodegenerative diseases.
Marlies Gijs
University Eye Clinic
University Maastricht, The Netherlands

The presentation will focus on the applications of tear fluid biomarkers in elderly populations, particularly in the diagnosis and monitoring of glaucoma and age-related neurodegenerative diseases. It will explore how these biomarkers can provide insights into disease progression, treatment response, and early detection of neurodegenerative changes.

Disclosures

Penny Asbell
Link Biologic, Premark, Regeneron, Santen, Abbvie, Amgen, Harrow, Glia, Senju, Trefoil, Azura, Iolyx, NIH

All other participants reported no relationships to disclose.

Bridging basic science and clinical research to unravel non-vascular changes in diabetic retinal disease

June 26 | Noon - 1:30pm

Organizers

Roomasa Channa
University of Wisconsin

Risa Wolf
Johns Hopkins University

Traditionally, retinal disease in diabetes has been primarily associated with vascular abnormalities. However, growing evidence suggests that retinal changes extend beyond the vasculature, affecting photoreceptors, nerve fibers, and electrophysiological function. This session will explore changes occurring in diabetic retinal disease, that affect retinal structures beyond the retinal vasculature, providing insights into their clinical implications and potential for early detection.

Panelists

Rithwick Rajagopal, MD, PhD
University of Washington

Mira Sachdeva, MD, PhD
Johns Hopkins University

Mitch Brigell, MD, PhD
Consultant to Opus Genetics, Inc.

Stela Vujosevic, MD, PhD
University Eye Clinic San Giuseppe Hospital Milan

Jennifer Sun, MD
Joslin Diabetes Center
Chief, Center for Clinical Eye Research and Trials
Beth Israel Deaconess Medical Center
Vice Chair of Clinical Research, Department of Surgery

Disclosures

Risa Wolf
Boehringer Ingelheim

Mitch Brigell, MD, PhD
Opus Genetics, Inc. Consultant

Stela Vujosevic, MD, PhD
Abbvie, apellis, boehringer Ingelheim , bayer, roche, adverum, annexon

Jennifer Sun, MD
F: Novartis, Genentech/Roche, Novo Nordisk, Optovue, Boehringer Ingelheim, Physical Sciences, Inc; R: Novo Nordisk, Boehringer Ingelheim, Alcon

All other participants reported no relationships to disclose.

Core outcome sets: Focusing on what matters

June 26 | Noon - 1:30pm

Organizers

Maria Teresa Sandinha
Liverpool University Hospitals, United Kingdom

Deidre Lane
Department of Cardiovascular and Metabolic Medicine, University of Liverpool, United Kingdom

Stephen Kaye
Department of Eye Vision Sciences, University of Liverpool, United Kingdom

The symposium will provide the attendees with a better understanding of what is a core outcome set (COS), as an agreed-upon minimum set of outcomes that should be measured and reported in all studies for a specific condition, population, or intervention. We also discuss why research studies  such as clinical trials, systematic reviews and meta-analyses, observational studies and health technology assessments will benefit from using these COS.

Panelists

Jamie Kirkham
Manchester University, United kingdom

Jignasa Mehta
Senior Lecturer in Orthoptics School of allied Health Professionals and Nursing, University of Liverpool
School of allied Health Professionals and Nursing, University of Liverpool. United Kingdom

Maria Teresa Sandinha
Consultant Vitreoretinal Surgeon, Liverpool University Hospitals and Honorary Senior Clinical Lecturer, University of Liverpool, United Kingdom

Stephen Kaye
Professor of Ophthalmology Eye & Vision Sciences
Institute of Life Course and Medical Sciences, University of Liverpool, United Kingdom
Department of Cardiovascular and Metabolic Medicine, University of Liverpool, United Kingdom

Disclosures

All participants reported no relationships to disclose.

 

SIG sessions registration
Sign up for virtual Special Interest Group sessions